Compare PLPC & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLPC | TBPH |
|---|---|---|
| Founded | 1947 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Water Sewer Pipeline Comm & Power Line Construction | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | N/A | N/A |
| Metric | PLPC | TBPH |
|---|---|---|
| Price | $239.20 | $19.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $27.80 |
| AVG Volume (30 Days) | 93.3K | ★ 379.1K |
| Earning Date | 03-12-2026 | 02-25-2026 |
| Dividend Yield | ★ 0.35% | N/A |
| EPS Growth | ★ 13.62 | N/A |
| EPS | ★ 7.55 | 0.58 |
| Revenue | ★ $663,346,000.00 | $80,327,000.00 |
| Revenue This Year | $16.31 | $70.78 |
| Revenue Next Year | $13.74 | N/A |
| P/E Ratio | ★ $31.40 | $34.88 |
| Revenue Growth | 15.93 | ★ 27.12 |
| 52 Week Low | $118.99 | $7.90 |
| 52 Week High | $251.67 | $21.03 |
| Indicator | PLPC | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 54.92 | 54.60 |
| Support Level | $235.89 | $19.53 |
| Resistance Level | $251.67 | $21.03 |
| Average True Range (ATR) | 10.10 | 0.82 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 63.75 | 57.05 |
Preformed Line Products Co is a designer and manufacturer of products and systems for constructing and maintaining overhead and underground networks for energy, telecommunication, cable operators, data communication, and other industries. In addition, it provides solar hardware systems and mounting hardware for a variety of solar power applications. Its products consist of Energy Products, Communications Products, and Special Industries Products. The company's majority of the revenue is derived from the sale of products in The Americas with operations also in PLP-USA, Europe, the Middle East and Africa, and Asia-Pacific. The revenue gets driven by Energy products which comprise protecting transmission conductors, spacers, spacer-dampers, and Stockbridge dampers.
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).